CAR-T Cell Therapy for Relapsed / Refractory CD19 Positive Clinical Study on the Safety and Effectiveness of Lymphoma

Trial Profile

CAR-T Cell Therapy for Relapsed / Refractory CD19 Positive Clinical Study on the Safety and Effectiveness of Lymphoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2018

At a glance

  • Drugs Anti-CD19-chimeric-antigen-receptor-T-cell-therapy-Sinobioway-Cell-Therapy (Primary)
  • Indications B cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Sinobioway Cell Therapy
  • Most Recent Events

    • 06 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top